CME (AMA PRA Category 1 Credit)

  2. Home
  3. Credit Type
  4. CME (AMA PRA Category 1 Credit)
  5. Specialty Area
  6. Cardiology
Results 1 - 49 of 49
9363-0001_263x1496
Microlearning: Reversing DOAC-associated Bleeds: The Right Approach for Each Patient
9363-0001_263x149
Microlearning: Uncontrolled DOAC-related Bleeding: Clinical Challenges, Unmet Needs
9363-0001_263x1495
Microlearning: Anticoagulation Reversal Agents - Current Approaches, Latest Research
tff-thumb9297
Module 3: Creating Patient-centric Treatment Plans
tff-thumb9297
Module 2: Enhancing NVAF Recognition - Whiteboard Animation
tff-thumb9297
Module 1: Insights Into Advances in NVAF - Animated Case
Image20230630173214
Seeing the Forest for the Trees: Recognizing Potential Amyloidosis
lyso
Emerging Biomarker Strategies for Lysosomal Storage Diseases
9444 fabry
A Focus on Fabry Disease: An EXPLORE™ eLearning Module
9191-icos
Treating & Assessing Treatment Response: AL Amyloidosis
Option05
The Advancing Treatment Landscape in Amyloidosis: Are You Ready?
9198-start
Stroke Prevention Through Afib Recognition & Treatment
No image set
PAH: Risk Reduction Strategies Using Single and Combination Therapies
No image set
How to Develop an Effective Risk Reduction Strategy in Pulmonary Arterial Hypertension
No image set
Pulmonary Arterial Hypertension (PAH) - Therapy Options Explained
No image set
Cardiac Amyloidosis: Is It A Zebra or A Horse? Webinar Summary Module
No image set
Cardiac Amyloidosis Webinar #4: Treatment of Cardiac Amyloidosis
No image set
Cardiac Amyloidosis Webinar #3: Establishing the Correct Diagnosis
No image set
Cardiac Amyloidosis Webinar #2: Cardiac Imaging Pearls
No image set
Cardiac Amyloidosis Webinar #1: Who Should I be Testing?
No image set
How to Choose the Right Therapy for Your Patients with IPF
No image set
PAH: Aligning Treatment Strategy to Risk Level
No image set
PAH: Identifying Side Effects and Optimizing Therapy to Improve Patient Outcomes
No image set
COVID-19 Acute and Long-term Lung Injury
No image set
COVID-19: An Animated Video Series
No image set
Learning From SARS and MERS: What Should We Expect for COVID-19 Patients
No image set
COVID-19 and Lung Injury/Fibrosis
No image set
Allergic Asthma: Virtual Conference Coverage
No image set
Conference Coverage on DMD & LGMD
No image set
Hereditary Transthyretin Amyloidosis: Case Studies
No image set
hATTR Amyloidosis: You and Your Family
9907-0005_cardio
Is It IPF or Cardiovascular Disease?
9916-kalluri
Advanced Care Planning and Palliative Care Models for Patients with IPF
9916-kalluri
Dyspnea Assessment in Patients with IPF
9916-scholand1
Which Patients with IPF Should be on Antifibrotics?
9916-brown5
The Impact of Anticoagulation Use on IPF Patient Outcomes
9916-brown5
Patient-Centered Outcomes for Patients with IPF: Activity Monitoring
9916-solomon
Connective Tissue Disease-Related ILD is Now in the Limelight
9916-brown5
Biomarkers in IPF and Other ILDs
9916-king
What are the Most Exciting Things Happening in Pulmonary Disease?
9916-scholand
New Tools to Improve the Diagnosis of IPF vs Other ILDs
9916-brown
New Research on Therapies for Patients with Pulmonary Fibrosis
9916-richeldi
The SENSCIS Trial: Exciting News for Scleroderma-Associated ILD
9916-cc-cme
2019 Summer Pulmonary Updates: The Experts Weigh In
med-doc-aatd
A Closer Look at Alpha-1 Antitrypsin Deficiency: Peggy’s Story
med-doc-ph
How Pulmonary Arterial Hypertension Has Changed Iain’s Life
9816-0010
Updates in Inoperable CTEPH
pah icon
PAH Today: Mastering Current, Tailored Treatment
No image set
Registry Data Provide Important Severity Indicators for PH

Search